251 related articles for article (PubMed ID: 25517442)
1. [PET radiopharmaceuticals: novelties and new possibilities].
Környei J; Mikecz P; Tóth G
Magy Onkol; 2014 Dec; 58(4):245-50. PubMed ID: 25517442
[TBL] [Abstract][Full Text] [Related]
2. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
[TBL] [Abstract][Full Text] [Related]
3. Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET.
Bunka M; Müller C; Vermeulen C; Haller S; Türler A; Schibli R; van der Meulen NP
Appl Radiat Isot; 2016 Apr; 110():129-133. PubMed ID: 26774390
[TBL] [Abstract][Full Text] [Related]
4. Quantitative imaging characteristics of zirconium-89 on Gemini Time-Of-Flight PET/CT.
Alanazi SF; Alzimami KS; Ghannam MM; Aljammaz IJ; Alrumayan F; Sassi SA
Nucl Med Commun; 2016 Dec; 37(12):1238-1245. PubMed ID: 27749774
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia imaging agents labeled with positron emitters.
Hoigebazar L; Jeong JM
Recent Results Cancer Res; 2013; 194():285-99. PubMed ID: 22918765
[TBL] [Abstract][Full Text] [Related]
6. The next generation of positron emission tomography radiopharmaceuticals in oncology.
Rice SL; Roney CA; Daumar P; Lewis JS
Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
[TBL] [Abstract][Full Text] [Related]
7. Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18.
Coenen HH; Ermert J
Nucl Med Biol; 2021 Jan; 92():241-269. PubMed ID: 32900582
[TBL] [Abstract][Full Text] [Related]
8. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
[TBL] [Abstract][Full Text] [Related]
9. [Oncology PET radiopharmaceuticals in clinic and research in 2020].
Mikecz P; Fekete A; Tóth G; Környei J; Bali T; Cservenyák T; Borbély K
Magy Onkol; 2020 Jun; 64(2):104-111. PubMed ID: 32520003
[TBL] [Abstract][Full Text] [Related]
10. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.
Ikotun OF; Lapi SE
Future Med Chem; 2011 Apr; 3(5):599-621. PubMed ID: 21526898
[TBL] [Abstract][Full Text] [Related]
11. Effective dose to staff members in a positron emission tomography/CT facility using zirconium-89.
Alzimami KS; Ma AK
Br J Radiol; 2013 Oct; 86(1030):20130318. PubMed ID: 23934963
[TBL] [Abstract][Full Text] [Related]
12. 44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?
Koumarianou E; Loktionova NS; Fellner M; Roesch F; Thews O; Pawlak D; Archimandritis SC; Mikolajczak R
Appl Radiat Isot; 2012 Dec; 70(12):2669-76. PubMed ID: 23037921
[TBL] [Abstract][Full Text] [Related]
13. PET tracers beyond FDG: normal variations and benign findings.
Kim CK; Beheshti M
PET Clin; 2014 Jul; 9(3):xi-xii. PubMed ID: 25030403
[No Abstract] [Full Text] [Related]
14. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.
Wadas TJ; Wong EH; Weisman GR; Anderson CJ
Chem Rev; 2010 May; 110(5):2858-902. PubMed ID: 20415480
[No Abstract] [Full Text] [Related]
15. Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.
Trencsényi G; Képes Z
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108559
[TBL] [Abstract][Full Text] [Related]
16. PET/MRI radiotracer beyond ¹⁸F-FDG.
Pampaloni MH; Nardo L
PET Clin; 2014 Jul; 9(3):345-9. PubMed ID: 25030398
[TBL] [Abstract][Full Text] [Related]
17. (68)Ga-radiopharmaceuticals for PET imaging of infection and inflammation.
Kumar V; Boddeti DK
Recent Results Cancer Res; 2013; 194():189-219. PubMed ID: 22918761
[TBL] [Abstract][Full Text] [Related]
18. [Current trends in using PET radiopharmaceuticals for diagnostics in oncology].
Adam J; Kadeřávek J; Kužel F; Vašina J; Rehák Z
Klin Onkol; 2014; 27 Suppl 1():S129-36. PubMed ID: 24945550
[TBL] [Abstract][Full Text] [Related]
19. Future direction of renal positron emission tomography.
Szabo Z; Xia J; Mathews WB; Brown PR
Semin Nucl Med; 2006 Jan; 36(1):36-50. PubMed ID: 16356795
[TBL] [Abstract][Full Text] [Related]
20. Review on production of 89Zr in a medical cyclotron for PET radiopharmaceuticals.
Kasbollah A; Eu P; Cowell S; Deb P
J Nucl Med Technol; 2013 Mar; 41(1):35-41. PubMed ID: 23327781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
